Detalles de la búsqueda
1.
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
Hepatology
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38768260
2.
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Clin Gastroenterol Hepatol
; 18(11): 2544-2553.e6, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32621971
3.
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Liver Int
; 40(10): 2385-2393, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32445613
4.
Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants.
J Int Assoc Physicians AIDS Care (Chic)
; 11(4): 252-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22544446
5.
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
HIV Clin Trials
; 12(5): 255-67, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22180523
6.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Gut Liver
; 15(6): 895-903, 2021 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34053916
7.
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Lancet Gastroenterol Hepatol
; 5(9): 839-849, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32682494
8.
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
HIV Clin Trials
; 10(2): 94-103, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19487179
9.
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
Int J Drug Policy
; 66: 73-79, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30735896
10.
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
J Pediatr
; 151(1): 34-42, 42.e1, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17586188
11.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Open Forum Infect Dis
; 4(3): ofx154, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28948180
12.
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
J Acquir Immune Defic Syndr
; 54(2): 143-51, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20134330
13.
Compliance with RSV prophylaxis: Global physicians' perspectives.
Patient Prefer Adherence
; 3: 195-203, 2009 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-19936162
Resultados
1 -
13
de 13
1
Próxima >
>>